Method for treating or preventing systemic inflammation in formula-fed infants
OwnerRobert McMahon, Josef Neuinventors
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a novel method for treating or preventing systemic inflammation in a formula-fed infant. The method comprises administering a therapeutically effective amount of LGG to the infant.
Claims19
A method for treating, preventing or reducing systemic inflammation in a formula-fed infant, the method comprising administering a therapeutically effective amount of LGG to the infant.
A method for reducing or preventing systemic inflammation in a formula-fed infant to a level similar to that of a breast-fed infant, the method comprising administering a therapeutically effective amount of LGG to the infant.
A method for reducing or preventing inflammation in one or more organs of a formula-fed infant selected from the group consisting of gastrointestinal tract, liver, plasma, lungs, and brain, the method comprising administering a therapeutically effective amount of LGG to the infant.
A method for reducing or preventing physical damage in the intestinal mucosa of a formula-fed infant, the method comprising administering a therapeutically effective amount of LGG to the infant.
The method according to claim 20, wherein the physical damage comprises a clearing of the cytoplasm, expansion of the lamina propria by a lymphoplasmacytic infiltrate, thinning of the muscularis mucosa, increased number and branching of crypts, and/or increased mitotic activity.
A method for reducing or preventing the systemic release of one or more pro-inflammatory cytokines or chemokines in a formula-fed infant, the method comprising administering a therapeutically effective amount of LGG to the infant.
The method according to claim 22, wherein the pro-inflammatory cytokine or chemokine comprises one or more selected from the group TNF-α, IL-1β, IL-6, IL-18 and GRO/KC.
The method according to claim 23, wherein the systemic release of TNF-α, IL-1β, IL-6 or IL-18 is reduced or prevented in the lung, liver, or plasma of the infant.
The method according to claim 23, wherein the systemic release of GRO/KC is reduced or prevented in the intestine, liver, plasma, or lung of the infant.
A method for reducing or preventing the systemic release of MPO in a formula-fed infant, the method comprising administering a therapeutically effective amount of LGG to the infant.
The method according to claim 26, wherein the systemic release of MPO is reduced or prevented in the intestine or lung of the infant.
Dependencies are inferred from the claim text.